Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1695234

registered interest
date	12/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	18214
answer	answer is ministerial correction date of answer 20/03/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).</p><p> </p><p>On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.</p><p> </p><p>Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 20/03/2024 17:11:23 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1694161

registered interest
date	06/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	17412
answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.</p><p> </p><p>The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 16:04:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1691367

registered interest
date	23/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department plans to take steps to ensure that every person with diabetes has access to medical technology that helps them manage their condition.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	15459
answer	answer is ministerial correction date of answer 29/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target.</p><p>In March 2023 the National Institute for Health and Care Excellence (NICE) recommended that insulin dependent patients with type 2 diabetes should also benefit from flash or continuous glucose monitoring devices. We are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p><p>On 19 December 2023 the NICE published its final recommendation on the hybrid closed loop system. The NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be the first to be offered a hybrid closed loop system, as part of a five-year roll-out plan. Access to hybrid closed loop systems will be through a five-year phased roll out, in line with NHS England’s implementation plans.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/02/2024 14:08:08 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4488 label Biography information for Martyn Day

1689034

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with type 1 diabetes use (a) finger-pricking monitoring and (b) continuous monitoring to track their glucose levels.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	13903
answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target. As a result of the recent National Institute for Health and Care Excellence guidance that also recommended that insulin dependent patients with type 2 diabetes should benefit from flash or continuous glucose monitoring devices, we are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13904 question first answered 21/02/2024 16:21:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth

1689035

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with type 1 diabetes use real time continuous glucose monitoring to manage their diabetes.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	13904
answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.</p><p>The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target. As a result of the recent National Institute for Health and Care Excellence guidance that also recommended that insulin dependent patients with type 2 diabetes should benefit from flash or continuous glucose monitoring devices, we are now starting to see a growth in prescribing within the type 2 diabetes patient group.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13903 question first answered 21/02/2024 16:21:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth

1689462

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department plans to take to support ICBs in increasing the adoption of real time continuous glucose monitoring for patients with type 2 diabetes.
tabling member constituency	Dewsbury
tabling member printed	Mark Eastwood
uin	14361
answer	answer is ministerial correction date of answer 26/02/2024 answer text <p>Diabetes care is commissioned by local integrated care boards (ICBs). ICBs are responsible for developing commissioning policies and making local decisions on how to utilise their funding.</p><p>Real time continuous glucose monitoring (CGM) for people living with type 1 and type 2 diabetes is prescribed in both primary and secondary care settings. Regrettably, as the reporting systems for secondary care prescribing varies across England, and depends on local commissioning arrangements, we do not have accurate figures for secondary care prescribing.</p><p>Our latest reports indicate that 70% of patients with type 1 diabetes in the West Yorkshire ICB are prescribed real time CGM in primary care. There will be additional patients who are prescribed real time CGM in secondary care, but we are unable to identify those patients from national reporting.</p><p>We are currently developing an alternative reporting model to provide reports that identify people with both type 1 and type 2 diabetes. The ICB recognises and continues to explore options to address the need for an end-to-end data solution for CGM and other diabetes technology, which allows the monitoring of access, uptake and health inequalities, care quality and safety, and spend.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14362 question first answered 26/02/2024 10:07:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4807 label Biography information for Mark Eastwood

1684916

registered interest
date	24/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of the availability of continuous glucose monitoring for people with type-1 diabetes; and if she will make an assessment of the potential merits of taking steps to increase access to that monitoring.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	11244
answer	answer is ministerial correction date of answer 06/02/2024 answer text <p>The NHS Long Term Plan made a commitment that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data up to the third quarter of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target. As a result of the recent National Institute for Health and Care Excellence guidance that also recommended that insulin dependent patients with type 2 diabetes should benefit from flash or continuous glucose monitoring devices, we are now starting to see a growth in prescription within the type 2 diabetes patient group.</p><p>Variation ratio in prescribing between the most and least affluent Indices of Multiple Deprivation (IMD) quintiles has been monitored on a quarterly basis. Variation between these IMD quintiles has reduced in every English region. When the programme started, Flash was twice as likely to be prescribed to patients living in the most affluent areas. The current ratio between most and least affluent geographies is now at a ratio of 1 to 1.02, meaning there is virtually parity between the most and least deprived patient groups across England.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 06/02/2024 17:40:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	298 label Biography information for Steve McCabe

1672463

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to monitor the effectiveness of hybrid closed loop technology implementation on (i) glycaemic control, (ii) quality of life and (iii) reduction in complications for patients.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	3354
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) has published their draft guidance on hybrid closed loop (HCL) technology for managing blood glucose levels in type 1 diabetes.</p><p>HCL technology represents a step change in care for patients living with type one diabetes, which is why NICE has agreed a five-year roll out of this technology with NHS England. This is to ensure the National Health Service has the staff training and patient support in place to safely roll out this new technology.</p><p>Access to medical devices should be determined by clinical need. It is our priority to ensure that all patients have access to the most innovative treatment options, wherever they live in the country.</p><p>Integrated care boards (ICBs) are responsible for developing a plan for meeting the health needs of their population, managing the NHS budget, and arranging for the provision of health services in the integrated care systems.</p><p>For HCL, NHS England will make clinicians aware of priority patients to help ensure equality of access and will keep this under review as it rolled out expands to other groups over the implementation period. NHS England will engage with patient representative groups, ICB leads, trust clinical leads working within children, young people and adult services, and professional bodies as part of the implementation strategy’s development.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 3355 3356 3357 question first answered 28/11/2023 12:43:13 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4769 label Biography information for Daisy Cooper

1672465

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to (a) involve patients with and (b) raise awareness of the (i) potential merits and (ii) availability of hybrid closed loop technology.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	3355
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) has published their draft guidance on hybrid closed loop (HCL) technology for managing blood glucose levels in type 1 diabetes.</p><p>HCL technology represents a step change in care for patients living with type one diabetes, which is why NICE has agreed a five-year roll out of this technology with NHS England. This is to ensure the National Health Service has the staff training and patient support in place to safely roll out this new technology.</p><p>Access to medical devices should be determined by clinical need. It is our priority to ensure that all patients have access to the most innovative treatment options, wherever they live in the country.</p><p>Integrated care boards (ICBs) are responsible for developing a plan for meeting the health needs of their population, managing the NHS budget, and arranging for the provision of health services in the integrated care systems.</p><p>For HCL, NHS England will make clinicians aware of priority patients to help ensure equality of access and will keep this under review as it rolled out expands to other groups over the implementation period. NHS England will engage with patient representative groups, ICB leads, trust clinical leads working within children, young people and adult services, and professional bodies as part of the implementation strategy’s development.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 3354 3356 3357 question first answered 28/11/2023 12:43:13 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4769 label Biography information for Daisy Cooper

1672466

registered interest
date	22/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure access to hybrid closed loop technology.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	3356
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) has published their draft guidance on hybrid closed loop (HCL) technology for managing blood glucose levels in type 1 diabetes.</p><p>HCL technology represents a step change in care for patients living with type one diabetes, which is why NICE has agreed a five-year roll out of this technology with NHS England. This is to ensure the National Health Service has the staff training and patient support in place to safely roll out this new technology.</p><p>Access to medical devices should be determined by clinical need. It is our priority to ensure that all patients have access to the most innovative treatment options, wherever they live in the country.</p><p>Integrated care boards (ICBs) are responsible for developing a plan for meeting the health needs of their population, managing the NHS budget, and arranging for the provision of health services in the integrated care systems.</p><p>For HCL, NHS England will make clinicians aware of priority patients to help ensure equality of access and will keep this under review as it rolled out expands to other groups over the implementation period. NHS England will engage with patient representative groups, ICB leads, trust clinical leads working within children, young people and adult services, and professional bodies as part of the implementation strategy’s development.</p><p> </p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 3354 3355 3357 question first answered 28/11/2023 12:43:13 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4769 label Biography information for Daisy Cooper